Bereich
Brustzentrum St.Gallen
BZ · Dept. IV
Effect of body mass index on response to neo-adjuvant therapy in HER2-positive breast cancer: an exploratory analysis of the NeoALTTO trial
Di Cosimo S, Daidone M, Piccart M, Izquierdo M, Fumagalli D, Huober J, Saura C, De Santis M, Franzoi M, Cinieri S, Agbor-Tarh D, Porcu L, de Azambuja E. Effect of body mass index on response to neo-adjuvant therapy in HER2-positive breast cancer: an exploratory analysis of the NeoALTTO trial. Breast Cancer Res 2020; 22:115.
27.10.2020Effect of body mass index on response to neo-adjuvant therapy in HER2-positive breast cancer: an exploratory analysis of the NeoALTTO trial
27.10.2020Breast Cancer Res 2020; 22:115
Di Cosimo Serena, Daidone Maria Grazia, Piccart Martine, Izquierdo Miguel, Fumagalli Debora, Huober Jens, Saura Cristina, De Santis Maria Carmen, Franzoi Maria Alice, Cinieri Saverio, Agbor-Tarh Dominique, Porcu Luca, de Azambuja Evandro
To which extent do breast cancer survivors feel well informed about disease and treatment 5 years after diagnosis?
Herbert S, Schwentner L, Fink V, Bekes I, Leinert E, Lato K, Polasik A, Schochter F, Singer S, Salmen J, Diessner J, Stüber T, Wöckel A, Kreienberg R, Kühn T, Flock F, Felberbaum R, Janni W, Curtaz C, Kiesel M, BRENDA study group. To which extent do breast cancer survivors feel well informed about disease and treatment 5 years after diagnosis?. Breast Cancer Res Treat 2020; 185:677-684.
26.10.2020To which extent do breast cancer survivors feel well informed about disease and treatment 5 years after diagnosis?
26.10.2020Breast Cancer Res Treat 2020; 185:677-684
Herbert S L, Schwentner L, Fink V, Bekes Inga, Leinert E, Lato K, Polasik A, Schochter F, Singer S, Salmen J, Diessner J, Stüber T, Wöckel A, Kreienberg R, Kühn T, Flock F, Felberbaum R, Janni W, Curtaz C, Kiesel M, BRENDA study group
Gemcitabine as adjuvant chemotherapy in patients with high-risk early breast cancer-results from the randomized phase III SUCCESS-A trial
De Gregorio A, Schneeweiss A, Tesch H, Mahner S, Brucker S, Blohmer J, Fehm T, Heinrich G, Lato K, Beckmann M, Rack B, Andergassen U, Bekes I, Fink V, Häberle L, Fasching P, Müller V, Schrader I, Lorenz R, Forstbauer H, Friedl T, Bauer E, De Gregorio N, Deniz M, Janni W. Gemcitabine as adjuvant chemotherapy in patients with high-risk early breast cancer-results from the randomized phase III SUCCESS-A trial. Breast Cancer Res 2020; 22:111.
23.10.2020Gemcitabine as adjuvant chemotherapy in patients with high-risk early breast cancer-results from the randomized phase III SUCCESS-A trial
23.10.2020Breast Cancer Res 2020; 22:111
De Gregorio Amelie, Schneeweiss Andreas, Tesch Hans, Mahner Sven, Brucker Sara Y, Blohmer Jens-Uwe, Fehm Tanja N, Heinrich Georg, Lato Krisztian, Beckmann Matthias W, Rack Brigitte, Andergassen Ulrich, Bekes Inga, Fink Visnja, Häberle Lothar, Fasching Peter A, Müller Volkmar, Schrader Iris, Lorenz Ralf, Forstbauer Helmut, Friedl Thomas W P, Bauer Emanuel, De Gregorio Nikolaus, Deniz Miriam, Janni Wolfgang
Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study)
Fasching P, Rhiem K, Schneeweiss A, Engels K, Denkert C, Schmutzler R, Hahnen E, Untch M, Burchardi N, Blohmer J, Loibl S, Doering G, Uleer C, Schmitt W, Link T, Hauke J, Seither F, Jackisch C, Klare P, Schmatloch S, Hanusch C, Huober J, Stefek A, Seiler S, German Breast Group and Arbeitsgemeinschaft Gynäkologische Onkologie Breast. Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study). Ann Oncol 2020; 32:49-57.
21.10.2020Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study)
21.10.2020Ann Oncol 2020; 32:49-57
Fasching P A, Rhiem K, Schneeweiss A, Engels K, Denkert C, Schmutzler R K, Hahnen E, Untch M, Burchardi N, Blohmer J-U, Loibl S, Doering G, Uleer C, Schmitt W D, Link T, Hauke J, Seither F, Jackisch C, Klare P, Schmatloch S, Hanusch C, Huober Jens, Stefek A, Seiler S, German Breast Group and Arbeitsgemeinschaft Gynäkologische Onkologie Breast
Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab
Michel L, Hielscher C, Mundhenke C, Kurbacher C, Wuerstlein R, Untch M, Overkamp F, Huober J, Janni W, Taran F, Lux M, Wallwiener D, Brucker S, Schneeweiss A, Wimberger P, Huebner H, Hartkopf A, Fasching P, Kolberg H, Hadji P, Tesch H, Häberle L, Ettl J, Luftner D, Wallwiener M, Müller V, Beckmann M, Belleville E, Volz B, Fehm T. Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab. Cancers (Basel) 2020; 12
17.10.2020Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab
17.10.2020Cancers (Basel) 2020; 12
Michel Laura L, Hielscher Carsten, Mundhenke Christoph, Kurbacher Christian, Wuerstlein Rachel, Untch Michael, Overkamp Friedrich, Huober Jens, Janni Wolfgang, Taran Florin-Andrei, Lux Michael P, Wallwiener Diethelm, Brucker Sara Y, Schneeweiss Andreas, Wimberger Pauline, Huebner Hanna, Hartkopf Andreas D, Fasching Peter A, Kolberg Hans-Christian, Hadji Peyman, Tesch Hans, Häberle Lothar, Ettl Johannes, Luftner Diana, Wallwiener Markus, Müller Volkmar, Beckmann Matthias W, Belleville Erik, Volz Bernhard, Fehm Tanja N
Management of Abemaciclib-Associated Adverse Events in Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3
Rugo H, Huober J, García-Sáenz J, Masuda N, Sohn J, Andre V, Barriga S, Cox J, Goetz M. Management of Abemaciclib-Associated Adverse Events in Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3. Oncologist 2020; 26:e53-e65.
09.10.2020Management of Abemaciclib-Associated Adverse Events in Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3
09.10.2020Oncologist 2020; 26:e53-e65
Rugo Hope S, Huober Jens, García-Sáenz José A, Masuda Norikazu, Sohn Joo Hyuk, Andre Valerie A M, Barriga Susana, Cox Joanne, Goetz Matthew
Generalkonsent: Verständlichkeit als ethische Dimension
Driessen S. Generalkonsent: Verständlichkeit als ethische Dimension. Schweiz Aerztezeitung 2020; 101:1306-1307.
07.10.2020Generalkonsent: Verständlichkeit als ethische Dimension
07.10.2020Schweiz Aerztezeitung 2020; 101:1306-1307
Driessen Susanne
nextMONARCH: Abemaciclib Monotherapy or Combined With Tamoxifen for Metastatic Breast Cancer
Hamilton E, Johnston E, Bear M, Hardebeck M, Lu Y, Chapman S, Huober J, Hegg R, Jerusalem G, Manikhas A, Petrakova K, Chen S, Ozyilkan O, Cortes J, Martín M. nextMONARCH: Abemaciclib Monotherapy or Combined With Tamoxifen for Metastatic Breast Cancer. Clin Breast Cancer 2020
30.09.2020nextMONARCH: Abemaciclib Monotherapy or Combined With Tamoxifen for Metastatic Breast Cancer
30.09.2020Clin Breast Cancer 2020
Hamilton Erika, Johnston Erica L, Bear Melissa M, Hardebeck Molly C, Lu Yi, Chapman Sonya C, Huober Jens, Hegg Roberto, Jerusalem Guy, Manikhas Aleksey, Petrakova Katarina, Chen Shin-Cheh, Ozyilkan Ozgur, Cortes Javier, Martín Miguel
Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE)
Johnston S, Huober J, Wardley A, Tolaney S, Cicin I, Smith I, Frenzel M, Headley D, Wei R, San Antonio B, Hulstijn M, Cox J, O'Shaughnessy J, Rastogi P, Cortes J, Neven P, Harbeck N, Hegg R, Toi M, Martín M, Shao Z, Zhang Q, Martinez Rodriguez J, Campone M, Hamilton E, Sohn J, Guarneri V, Okada M, Boyle F, monarchE Committee Members and Investigators. Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE). J Clin Oncol 2020; 38:3987-3998.
20.09.2020Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE)
20.09.2020J Clin Oncol 2020; 38:3987-3998
Johnston Stephen R D, Huober Jens, Wardley Andrew, Tolaney Sara M, Cicin Irfan, Smith Ian C, Frenzel Martin, Headley Desirée, Wei Ran, San Antonio Belen, Hulstijn Maarten, Cox Joanne, O'Shaughnessy Joyce, Rastogi Priya, Cortes Javier, Neven Patrick, Harbeck Nadia, Hegg Roberto, Toi Masakazu, Martín Miguel, Shao Zhi Min, Zhang Qing Yuan, Martinez Rodriguez Jorge Luis, Campone Mario, Hamilton Erika, Sohn Joohyuk, Guarneri Valentina, Okada Morihito, Boyle Frances, monarchE Committee Members and Investigators
Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany
Schneeweiss A, Lux M, Müller V, Nabieva N, Overkamp F, Tesch H, Laakmann E, Taran F, Seitz J, Thomssen C, Untch M, Wimberger P, Wuerstlein R, Volz B, Wallwiener D, Wallwiener M, Klein E, Kurbacher C, Ettl J, Luftner D, Beckmann M, Belleville E, Fasching P, Fehm T, Geberth M, Häberle L, Hadji P, Hartkopf A, Hielscher C, Huober J, Ruckhäberle E, Janni W, Kolberg H, Brucker S. Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany. Breast 2020; 54:88-95.
29.08.2020Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany
29.08.2020Breast 2020; 54:88-95
Schneeweiss Andreas, Lux Michael P, Müller Volkmar, Nabieva Naiba, Overkamp Friedrich, Tesch Hans, Laakmann Elena, Taran Florin-Andrei, Seitz Julia, Thomssen Christoph, Untch Michael, Wimberger Pauline, Wuerstlein Rachel, Volz Bernhard, Wallwiener Diethelm, Wallwiener Markus, Klein Evelyn, Kurbacher Christian M, Ettl Johannes, Luftner Diana, Beckmann Matthias W, Belleville Erik, Fasching Peter A, Fehm Tanja N, Geberth Matthias, Häberle Lothar, Hadji Peyman, Hartkopf Andreas D, Hielscher Carsten, Huober Jens, Ruckhäberle Eugen, Janni Wolfgang, Kolberg Hans Christian, Brucker Sara Y
Surgical Outcomes After Neoadjuvant Chemoradiation Followed by Curative Surgery in Patients With Esophageal Cancer: An Intergroup Phase lll Trial of the Swiss Group for Clinical Cancer Research (SAKK 75/08)
von Holzen U, Függer R, Königsrainer A, Gloor B, Furrer M, Gerard M, Hawle H, Walz M, Alesina P, Schäfer M, Marti W, Kettelhack C, Schmidt S, Hayoz S, Steffen T, Grieder F, Bartsch D, Schnider A, Knoefel W, Piessen G, Ruhstaller T. Surgical Outcomes After Neoadjuvant Chemoradiation Followed by Curative Surgery in Patients With Esophageal Cancer: An Intergroup Phase lll Trial of the Swiss Group for Clinical Cancer Research (SAKK 75/08). Ann Surg 2020
26.08.2020Surgical Outcomes After Neoadjuvant Chemoradiation Followed by Curative Surgery in Patients With Esophageal Cancer: An Intergroup Phase lll Trial of the Swiss Group for Clinical Cancer Research (SAKK 75/08)
26.08.2020Ann Surg 2020
von Holzen Urs, Függer Reinhold, Königsrainer Alfred, Gloor Beat, Furrer Markus, Gerard Marie-Aline, Hawle Hanne, Walz Martin K, Alesina Piero, Schäfer Markus, Marti Walter R, Kettelhack Christoph, Schmidt Sven, Hayoz Stefanie, Steffen Thomas, Grieder Felix, Bartsch Detlef, Schnider Annelies, Knoefel Wolfram-Trudo, Piessen Guillaume, Ruhstaller Thomas
Uncertainties about the need for ethics approval in Switzerland: a mixed-methods study.
Gloy V, McLennan S, Rinderknecht M, Ley B, Meier B, Driessen S, Gervasoni P, Hirschel B, Benkert P, Gilles I, von Elm E, Briel M. Uncertainties about the need for ethics approval in Switzerland: a mixed-methods study. Swiss Med Wkly 2020; 150:w20318.
12.08.2020Uncertainties about the need for ethics approval in Switzerland: a mixed-methods study.
12.08.2020Swiss Med Wkly 2020; 150:w20318
Gloy Viktoria, McLennan Stuart, Rinderknecht Matthias, Ley Bettina, Meier Brigitte, Driessen Susanne, Gervasoni Pietro, Hirschel Bernard, Benkert Pascal, Gilles Ingrid, von Elm Erik, Briel Matthias
Diagnosing Pathologic Complete Response in the Breast After Neoadjuvant Systemic Treatment of Breast Cancer Patients by Minimal Invasive Biopsy: Oral Presentation at the San Antonio Breast Cancer Symposium on Friday, December 13, 2019, Program Number GS5-03
Heil J, Friedrichs K, Wojcinski S, Joos S, Paepke S, Ditsch N, Rody A, Große R, van Mackelenbergh M, Reinisch M, Karsten M, Golatta M, Bekes I, Malter W, Hackmann J, Pfob A, Sinn H, Rauch G, Bach P, Thomas B, Schaefgen B, Kuemmel S, Reimer T, Hahn M, Thill M, Blohmer J, RESPONDER Investigators. Diagnosing Pathologic Complete Response in the Breast After Neoadjuvant Systemic Treatment of Breast Cancer Patients by Minimal Invasive Biopsy: Oral Presentation at the San Antonio Breast Cancer Symposium on Friday, December 13, 2019, Program Number GS5-03. Ann Surg 2020
09.07.2020Diagnosing Pathologic Complete Response in the Breast After Neoadjuvant Systemic Treatment of Breast Cancer Patients by Minimal Invasive Biopsy: Oral Presentation at the San Antonio Breast Cancer Symposium on Friday, December 13, 2019, Program Number GS5-03
09.07.2020Ann Surg 2020
Heil Joerg, Friedrichs Kay, Wojcinski Sebastian, Joos Sylvie, Paepke Stefan, Ditsch Nina, Rody Achim, Große Regina, van Mackelenbergh Marion, Reinisch Mattea, Karsten Maria, Golatta Michael, Bekes Inga, Malter Wolfram, Hackmann John, Pfob André, Sinn Hans-Peter, Rauch Geraldine, Bach Paul, Thomas Bettina, Schaefgen Benedikt, Kuemmel Sherko, Reimer Toralf, Hahn Markus, Thill Marc, Blohmer Jens-Uwe, RESPONDER Investigators
Identifying oncogenic drivers associated with increased risk of late distant recurrence in postmenopausal, estrogen receptor-positive, HER2-negative early breast cancer: results from the BIG 1-98 study
Luen S, Regan M, Colleoni M, Di Leo A, Viale G, Thürlimann B, Hackl W, Demanse D, Biasi O, Dell'orto P, Kammler R, Savas P, Lee C, Asher R, Loi S. Identifying oncogenic drivers associated with increased risk of late distant recurrence in postmenopausal, estrogen receptor-positive, HER2-negative early breast cancer: results from the BIG 1-98 study. Ann Oncol 2020; 31:1359-1365.
08.07.2020Identifying oncogenic drivers associated with increased risk of late distant recurrence in postmenopausal, estrogen receptor-positive, HER2-negative early breast cancer: results from the BIG 1-98 study
08.07.2020Ann Oncol 2020; 31:1359-1365
Luen S J, Regan M M, Colleoni M, Di Leo A, Viale G, Thürlimann Beat, Hackl W, Demanse D, Biasi O M, Dell'orto P, Kammler R, Savas P, Lee C K, Asher R, Loi S
Health-Related Quality of Life in MONARCH 3: Abemaciclib plus an Aromatase Inhibitor as Initial Therapy in HR+, HER2- Advanced Breast Cancer
Goetz M, Price G, Gainford M, Andre V, Shekarriz S, Stoffregen C, Toi M, Huober J, Park I, Tokunaga E, Martín M, Johnston S. Health-Related Quality of Life in MONARCH 3: Abemaciclib plus an Aromatase Inhibitor as Initial Therapy in HR+, HER2- Advanced Breast Cancer. Oncologist 2020; 25:e1346-e1354.
24.06.2020Health-Related Quality of Life in MONARCH 3: Abemaciclib plus an Aromatase Inhibitor as Initial Therapy in HR+, HER2- Advanced Breast Cancer
24.06.2020Oncologist 2020; 25:e1346-e1354
Goetz Matthew P, Price Gregory L, Gainford M Corona, Andre Valerie, Shekarriz Sarah, Stoffregen Clemens, Toi Masakazu, Huober Jens, Park In Hae, Tokunaga Eriko, Martín Miguel, Johnston Stephen
Consolidation cetuximab after concurrent triplet radiochemotherapy+cetuximab in patients with advanced head and neck cancer: A randomized phase II study.
Riesterer O, Pruschy M, Bender S, Sharma A, Bogowicz M, Tanadini-Lang S, Stieb S, Bertogg K, Weber S, Ikenberg K, Huber G, Schmid S, Bredell M, Veit-Haibach P, Rordorf T, Held U, Glanzmann C, Studer G. Consolidation cetuximab after concurrent triplet radiochemotherapy+cetuximab in patients with advanced head and neck cancer: A randomized phase II study. Radiother Oncol 2020; 150:62-69.
12.06.2020Consolidation cetuximab after concurrent triplet radiochemotherapy+cetuximab in patients with advanced head and neck cancer: A randomized phase II study.
12.06.2020Radiother Oncol 2020; 150:62-69
Riesterer Oliver, Pruschy Martin, Bender Sabine, Sharma Ashish, Bogowicz Marta, Tanadini-Lang Stephanie, Stieb Sonja, Bertogg Kaja, Weber Sandra, Ikenberg Kristian, Huber Gerhard, Schmid Stephan, Bredell Marius, Veit-Haibach Patrick, Rordorf Tamara, Held Ulrike, Glanzmann Christoph, Studer Gabriela
AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2020
Thill M, Mundhenke C, Moebus V, Maass N, Lux M, Luftner D, Loibl S, Kümmel S, Kühn T, Kreipe H, Park-Simon T, Reimer T, Rhiem K, Wöckel A, Witzel I, Thomssen C, Stickeler E, Solomayer E, Solbach C, Schneeweiss A, Schmidt M, Rody A, Huober J, Heil J, Banys-Paluchowski M, Albert U, Müller V, Janni W, Friedrich M, Krug D, Jackisch C, Kolberg-Liedtke C, Untch M, Bauerfeind I, Blohmer J, Budach W, Harbeck N, Hanf V, Gluz O, Gerber B, Fehm T, Fasching P, Fallenberg E, Diel I, Dall P, Ditsch N. AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2020. Breast Care (Basel) 2020; 15:294-309.
10.06.2020AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2020
10.06.2020Breast Care (Basel) 2020; 15:294-309
Thill Marc, Mundhenke Christoph, Moebus Volker, Maass Nicolai, Lux Michael, Luftner Diana, Loibl Sibylle, Kümmel Sherko, Kühn Thorsten, Kreipe Hans H, Park-Simon Tjoung-Won, Reimer Toralf, Rhiem Kerstin, Wöckel Achim, Witzel Isabell, Thomssen Christoph, Stickeler Elmar, Solomayer Erich-Franz, Solbach Chistine, Schneeweiss Andreas, Schmidt Marcus, Rody Achim, Huober Jens, Heil Jörg, Banys-Paluchowski Malgorzata, Albert Ute-Susann, Müller Volkmar, Janni Wolfgang, Friedrich Michael, Krug David, Jackisch Christian, Kolberg-Liedtke Cornelia, Untch Michael, Bauerfeind Ingo, Blohmer Jens-Uwe, Budach Wilfried, Harbeck Nadia, Hanf Volker, Gluz Oleg, Gerber Bernd, Fehm Tanja, Fasching Peter A, Fallenberg Eva Maria, Diel Ingo, Dall Peter, Ditsch Nina
Beneficial Molecular Adaptations In -Mutation Carriers By Combined HIT/HIRT Intervention: Results From A Pilot Study
Bizjak D, Janni W, Huober J, Leinert E, Ebner F, Kirsten J, Otto S, Schumann U, Schulz S, Steinacker J. Beneficial Molecular Adaptations In -Mutation Carriers By Combined HIT/HIRT Intervention: Results From A Pilot Study. Cancers (Basel) 2020; 12
10.06.2020Beneficial Molecular Adaptations In -Mutation Carriers By Combined HIT/HIRT Intervention: Results From A Pilot Study
10.06.2020Cancers (Basel) 2020; 12
Bizjak Daniel A, Janni Wolfgang, Huober Jens, Leinert Elena, Ebner Florian, Kirsten Johannes, Otto Stephanie, Schumann Uwe, Schulz Sebastian V W, Steinacker Jürgen Michael
Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo
Karn T, Schmitt W, Wu S, van Mackelenbergh M, Müller V, Schem C, Stickeler E, Fasching P, Jackisch C, Untch M, Schneeweiss A, Marmé F, Blohmer J, Denkert C, Weber K, Holtrich U, Hanusch C, Sinn B, Higgs B, Jank P, Sinn H, Huober J, Becker C, Loibl S. Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo. Ann Oncol 2020; 31:1216-1222.
24.05.2020Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo
24.05.2020Ann Oncol 2020; 31:1216-1222
Karn T, Schmitt W D, Wu S, van Mackelenbergh M, Müller V, Schem C, Stickeler E, Fasching P A, Jackisch C, Untch M, Schneeweiss A, Marmé F, Blohmer J-U, Denkert C, Weber K E, Holtrich U, Hanusch C, Sinn B V, Higgs B W, Jank P, Sinn H P, Huober Jens, Becker C, Loibl S
Central Review of Radiation Therapy Planning Among Patients with Breast-Conserving Surgery: Results from a Quality Assurance Process Integrated into the INSEMA Trial
Hildebrandt G, Loibl S, Bekes I, Nekljudova V, Heil J, Reitsamer R, Kaiser J, Sedlmayer F, Zierhut D, Kühn T, Wolter K, Krug D, Potenberg J, Gerber B, Stachs A, Reimer T. Central Review of Radiation Therapy Planning Among Patients with Breast-Conserving Surgery: Results from a Quality Assurance Process Integrated into the INSEMA Trial. Int J Radiat Oncol Biol Phys 2020; 107:683-693.
11.05.2020Central Review of Radiation Therapy Planning Among Patients with Breast-Conserving Surgery: Results from a Quality Assurance Process Integrated into the INSEMA Trial
11.05.2020Int J Radiat Oncol Biol Phys 2020; 107:683-693
Hildebrandt Guido, Loibl Sibylle, Bekes Inga, Nekljudova Valentina, Heil Jörg, Reitsamer Roland, Kaiser Julia, Sedlmayer Felix, Zierhut Dietmar, Kühn Thorsten, Wolter Kathi, Krug David, Potenberg Jochem, Gerber Bernd, Stachs Angrit, Reimer Toralf